Oralair (Allergen Extract From Pollen Of Dactylis Glomerata, Anthoxanthum Odoratum, Lolium Perenne, Poa Prate)

Oralair is an allergen immunotherapy that targets grass‑pollen‑related allergic disease.

• Grass pollen allergic rhinitis: reduces nasal congestion, sneezing and itching during the grass season.
• Seasonal allergic rhinoconjunctivitis (grass): improves overall symptom control and quality of life.
• Grass‑induced allergic asthma (adjunct): may lessen asthma exacerbations linked to grass exposure.

• Oralair contains standardized grass‑pollen allergen extracts that are administered sublingually. Repeated exposure induces immune tolerance by shifting the T‑cell response from a Th2‑dominant profile toward regulatory T‑cells, increasing allergen‑specific IgG4 and decreasing IgE‑mediated mast cell activation, thereby reducing clinical reactivity to grass pollen.

Adverse reactions are generally localized to the oral cavity but can range from mild to severe.

Common Side Effects

• Oral itching or tingling: mild discomfort in the mouth after dosing.
• Throat irritation: transient soreness or scratchy sensation.
• Ear pruritus: itching in the ears or around the jaw.
• Mild gastrointestinal upset: nausea or mild stomach discomfort.
• Local swelling of the tongue or lips: transient and self‑limiting.

Serious or Rare Side Effects

• Anaphylaxis: rapid onset of systemic allergic reaction requiring emergency care.
• Severe systemic allergic reaction: widespread urticaria, angioedema, or respiratory distress.
• Asthma exacerbation: worsening of underlying asthma symptoms.
• Severe oral edema: pronounced swelling that interferes with breathing or swallowing.
• Cardiovascular collapse: rare but life‑threatening drop in blood pressure.

Oralair should be used with careful patient selection and monitoring.

• Contraindication: severe uncontrolled asthma: avoid use until asthma is stable.
• Pregnancy: limited data, use only if potential benefit outweighs risk.
• Breastfeeding: no specific studies, consider risk‑benefit before prescribing.
• Monitoring: observe patients for at least 30 minutes after first dose for systemic reactions.
• Drug interactions: inform patients about possible interactions with immunosuppressants.
• Storage: Store at ambient temperature below 25°C: keep in original container, protect from moisture and direct sunlight.

Oralair may interact with other agents that affect immune response or mask allergic symptoms.

Major Interactions (Avoid)

• Beta‑blockers: may blunt response to emergency epinephrine during anaphylaxis.
• Immunosuppressive therapy (e.g., high‑dose steroids, chemotherapy): may reduce efficacy of immunotherapy.

Moderate Interactions (Monitor Closely)

• Antihistamines: can mask early local reactions, making monitoring harder.
• Systemic corticosteroids: may alter immune modulation during treatment.
• Omalizumab (anti‑IgE): may affect the clinical response to allergen extracts.
• Live vaccines: schedule administration to avoid overlapping immune activation.